Multiple Myeloma
Conditions
Keywords
Multiple Myeloma, Myeloma, Myeloma Multiple, CC-98633, BCMA, CAR-T, CART, BCMA CART, BCMA CAR-T
Brief summary
This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in participants with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of increasing dose levels of CC-98633 to establish a recommended Phase 2 dose RP2D(s); and the dose-expansion part (Part B) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of CC-98633 at the RP2D(s).
Interventions
BIOLOGICALCC-98633
Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633. During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy. Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection.
Sponsors
Juno Therapeutics, a Subsidiary of Celgene
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years. 2. Signed written informed consent prior to any study procedure. 3. Relapsed and/or refractory multiple myeloma (MM). 1. Subjects must have documented progressive disease as per International Myeloma Working Group (IMWG) criteria during or within 12 months of completing treatment with the last anti-myeloma treatment regimen before study entry. Also, subjects with confirmed progressive disease within 6 months prior to start of Screening and who are refractory (or non-responsive) to their most recent anti-myeloma treatment regimen afterwards will be also eligible. 2. Part A and Part B Cohort A: Subjects must have confirmed at least 3 prior antimyeloma treatment regimens. 3. Part B Cohort B only: Subjects must have received at least 1 but no greater than 3 prior antimyeloma treatment regimens, including a proteasome inhibitor and immunomodulatory agent. 4. Subjects must have previously received all of the following therapies: i) Autologous stem cell transplant ii) A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib), either alone or combination iii) Anti-CD38 (eg, daratumumab), either alone or combination Subjects in Cohort B do not require prior anti-CD38 antibody therapy. 4. Measurable disease 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 6. Adequate organ function
Exclusion criteria
1. Known active or history of central nervous system (CNS) involvement of MM 2. Active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis 3. Prior treatment with CAR T-cell or another genetically modified T-cell therapy 4. Part A and Part B Cohort A only: Prior treatment with investigational therapy directed at BCMA 5. Uncontrolled or active infection 6. Active autoimmune disease requiring immunosuppressive therapy 7. History or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events (AEs) | From the time of informed consent and follow up to 2 years after infusion of CC-98633: | incidence and severity of AEs. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response (CR) Rate | Up to 2 years after CC-99633 infusion | The proportion of subjects achieving stringent CR or CR. |
| Duration of response (DOR) | Up to 2 years after CC-98633 infusion | The time from first response (sCR, CR, VGPR, or PR) to progressive disease (PD) or death. |
| Time to response (TTR) | Up to 2 years after CC-98633 infusion | Time from CC-98633 infusion to the first documentation of response (sCR, CR, VGPR or PR). |
| Time to complete response (TTCR) | Up to 2 years after CC-98633 infusion | Time from CC-98633 infusion to the first documentation of sCR or CR |
| Progression free survival (PFS) | Up to 2 years after CC-98633 infusion | Time from CC-98633 infusion to the first documentation of PD, or death from any cause, whichever occurs first |
| Overall Response Rate (ORR) | Up to 2 years after CC-98633 infusion | The proportion of subjects with a partial response (PR) or better by the IMWG criteria. |
| Pharmacokinetics - maximum serum concentration (Cmax) | Up to 2 years after CC-98633 infusion | Maximum blood concentration |
| Pharmacokinetics -time to peak serum concentration (tmax) | Up to 2 years after CC-98633 infusion | Time to peak (maximum) blood concentration |
| Pharmacokinetics - Area under curve (AUC) | Up to 2 years after CC-98633 infusion | Area under the curve |
| Very good partial response (VGPR) or better | Up to 2 years after CC-98633 infusion | Is define as proportion of subjects achieving sCR, CR, or VGPR |
| Overall survival (OS) | Up to 2 years after CC-98633 infusion | Time from CC-98633 infusion to death |
Countries
United States
Outcome results
None listed